Indian Court Hands Novartis Setback In Gleevec Patent Case
This article was originally published in PharmAsia News
Executive Summary
Novartis suffered a major blow Aug. 6 when an Indian court dismissed its challenge of a key government provision that blocks the company from obtaining a patent for its oncologic Gleevec (imatinib)
You may also be interested in...
IP Protection Concerns Grow In India, PhRMA Says
Intellectual property protection in India is an increasing concern for industry following a year of regulatory action and inaction, according to the Pharmaceutical Research and Manufacturers of America
IP Protection Concerns Grow In India, PhRMA Says
Intellectual property protection in India is an increasing concern for industry following a year of regulatory action and inaction, according to the Pharmaceutical Research and Manufacturers of America
Lost In Bureaucracy? Novartis Gleevec IP Case Held Up By Indian Legal System
Patent case for new form of imatinib will now be reviewed by newly formed Intellectual Property Appellate Board.